Safety and Tolerability of M254 in Healthy Volunteers and Immune Thrombocytopenic Purpura (ITP) Patients

Stopped early · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Immune Thrombocytopenic Purpura (ITP)

In brief

The purpose of this study is to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of M254 after administration of a single ascending dose and repeat doses in healthy volunteers and immune thrombocytopenic purpura (ITP) patients. The pharmacodynamics of the drug will be measured as platelet response in patients with ITP.

Key facts

Study ID
NCT03866577
Run by
Momenta Pharmaceuticals, Inc.
People needed
50
Starts
2018-12-21
Expected to finish
2021-06-09
Last updated by the study team
2025-05-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.